Lipoprotein Drug Delivery Initiative: A Translational research program employing the HDL and HDL mimetic drug delivery platform.

Simple item page
dc.contributor.authorRaut, Sangram
dc.contributor.authorFudala, Rafal
dc.contributor.authorLacko, Andras G.
dc.contributor.authorSaranya Conjeevaram Nagarajan, Bhavani
dc.contributor.authorDossou, Akpedie
dc.creatorSabnis, Nirupama
dc.date.accessioned2020-12-10T20:27:10Z
dc.date.available2020-12-10T20:27:10Z
dc.date.issued2020
dc.description.abstractReconstituted (synthetic) lipoproteins and lipoprotein mimetics have been recognized as a superior biocompatible, targeted drug-delivery platform and thus have great potential in the treatment of a number of diseases. Our laboratory has been involved in exploiting the potential of rHDL nanoparticles (NPs) in cancer theranostics. Traditional chemotherapy is afflicted with long and short term side effects due to off target delivery of anti-cancer agents. In fact, often the side effects prove more damaging to the patients than the disease itself. Lipoprotein-based technologies could address this challenge due to their ability to selectively deliver their payload to cancer cells and tumors, via a receptor mediated mechanism. The therapeutic index (side effect profile) of a drug can thus be significantly improved by directing the selective delivery capabilities of the rHDL NPs toward tumors but not toward normal tissues. The contributions of our laboratory in facilitating the progress of this technology toward its clinical applications for the treatment of cancers are highlighted in this presentation.
dc.identifier.urihttps://hdl.handle.net/20.500.12503/30083
dc.language.isoen
dc.titleLipoprotein Drug Delivery Initiative: A Translational research program employing the HDL and HDL mimetic drug delivery platform.
dc.typeposter
dc.type.materialtext

Files

Collections

Cancer